Navigation Links
Isis Initiates Phase 1 Clinical Trial of SGLT2 Antisense Drug
Date:2/5/2009

ents reflect the good faith judgment of its management, these statements are based only on facts and factors currently known by Isis. As a result, you are cautioned not to rely on these forward-looking statements. These and other risks concerning Isis' programs are described in additional detail in Isis' annual report on Form 10-K for the year ended December 31, 2007, and its most recent quarterly report on Form 10-Q, which are on file with the SEC. Copies of these and other documents are available from the Company.

In this press release, unless the context requires otherwise, "Isis," "Company," "we," "our," and "us" refers to Isis Pharmaceuticals and its subsidiaries and joint venture.

Isis Pharmaceuticals is a registered trademark of Isis Pharmaceuticals, Inc. Regulus Therapeutics is a trademark of Regulus Therapeutics Inc.


'/>"/>
SOURCE Isis Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4

Related biology technology :

1. Romark Initiates Clinical Trial of Alinia(R) for Chronic Hepatitis C in the United States
2. Dawson James Securities Initiates Research Coverage on CryoCor, Inc. (Nasdaq: CRYO) with a Strong Buy Rating and $6.00 Target Price
3. Spectrum Pharmaceuticals Initiates Second Registrational Phase 3 Clinical Trial for EOquin(R) in Patients With Non-Invasive Bladder Cancer
4. XTL Biopharmaceuticals Initiates Phase IIb Clinical Trial of Bicifadine for the Treatment of Diabetic Neuropathic Pain
5. Nventa Initiates HspE7 Phase 1 Cervical Dysplasia Trial
6. Cytochroma initiates Phase I/II clinical trial of CTAP101 Capsules for vitamin D insufficiency in chronic kidney disease
7. Arena Pharmaceuticals Initiates Second and Third Pivotal Trials Evaluating Lorcaserin for the Treatment of Obesity
8. GeneNews initiates patient sample accrual for validation studies of colon cancer blood test
9. Human Genome Sciences Initiates Second Randomized Phase 2 Trial of HGS-ETR1 in Combination With Chemotherapy
10. Conatus Pharmaceuticals Initiates a Phase 2 Clinical Trial for the Treatment of Hepatitis
11. Memory Pharmaceuticals Initiates Phase 2a Trial of MEM 3454 in Cognitive Impairment Associated with Schizophrenia

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/25/2009)...W YORK, Nov. 25 Reportlinker.com a...lable in its catalogue: ,, Brazil Bioethanol M...//www.reportlinker.com/p0165503/Brazil-Bioethanol-...Brazil Bioethanol Market Analysis and Forecasts to...tailed analysis and forecasts of the global bioeth...
(Date:11/24/2009)... Ambassador to also Visit Detroit , ...Who: David Appia, French Ambassador for Internatio... in France Agency, , , , ,What: Ambassador Appia ...pro-business initiatives adopted by France to furt...dscape for innovation and development., , ,When: A...
(Date:11/24/2009)..., REYKJAVIK, Iceland, November 24 /PRNewswi...GN ) today announced that it has received notice f...mpany,s common stock will be,suspended as of Novem...the,Securities and Exchange Commission, which will...aq, unless the company files an appeal to the Nasd...
(Date:11/24/2009)...HANGHAI, Nov. 24 /PRNewswire-Asia/ -- NOD Pharmace...rk Office (PTO) has allowed the patent application...logy. , NOD technology is a highly effici...nto bio-adhesive nano-particles to enable oral del...s. NOD technology is a platform technology,that ca...
Breaking Biology Technology:Reportlinker Adds Brazil Bioethanol Market Analysis and Forecasts to 2013 2Reportlinker Adds Brazil Bioethanol Market Analysis and Forecasts to 2013 3Reportlinker Adds Brazil Bioethanol Market Analysis and Forecasts to 2013 4Reportlinker Adds Brazil Bioethanol Market Analysis and Forecasts to 2013 5Reportlinker Adds Brazil Bioethanol Market Analysis and Forecasts to 2013 6Reportlinker Adds Brazil Bioethanol Market Analysis and Forecasts to 2013 7Reportlinker Adds Brazil Bioethanol Market Analysis and Forecasts to 2013 8Reportlinker Adds Brazil Bioethanol Market Analysis and Forecasts to 2013 9Reportlinker Adds Brazil Bioethanol Market Analysis and Forecasts to 2013 10deCODE Receives Delisting Notice From Nasdaq, Plans to Appeal 2deCODE Receives Delisting Notice From Nasdaq, Plans to Appeal 3
...dingBlocks is market,s first service for pre-purch..., Dec. 9 The Scientific business of Thomson Reute... source for online access to industry codes and st... BuildingBlocks utility, allowing engineers to pre...hers such as ASTM (American Society for Testing a...
...H SAN FRANCISCO, Calif., Dec. 9 Proteolix, Inc. t...g that the company,s lead,product, carfilzomib, ha...nses,in patients with relapsed and refractory mult...lass of specific proteasome inhibitors being devel... malignancies and solid tumors. , Sundar Jag...
...TO, Calif., Dec. 9 BioMarin Pharmaceutical,Inc. (...Merck Serono, a division,of Merck KGaA, Darmstadt,...n(R) (sapropterin dihydrochloride) for the treatme...ia (PKU) or BH4 deficient patients,from the Europe...are,approximately 35,000 patients diagnosed with h...
Other Biology Technology:Techstreet Launches BuildingBlocks Utility for Industry Standards Saving Time and Increasing Productivity for Engineers 2Proteolix Announces Positive Data From Two Ongoing Phase 2 Clinical Trials of Carfilzomib in Multiple Myeloma at the 50th Annual Meeting of the American Society of Hematology 2Proteolix Announces Positive Data From Two Ongoing Phase 2 Clinical Trials of Carfilzomib in Multiple Myeloma at the 50th Annual Meeting of the American Society of Hematology 3Proteolix Announces Positive Data From Two Ongoing Phase 2 Clinical Trials of Carfilzomib in Multiple Myeloma at the 50th Annual Meeting of the American Society of Hematology 4Proteolix Announces Positive Data From Two Ongoing Phase 2 Clinical Trials of Carfilzomib in Multiple Myeloma at the 50th Annual Meeting of the American Society of Hematology 5Proteolix Announces Positive Data From Two Ongoing Phase 2 Clinical Trials of Carfilzomib in Multiple Myeloma at the 50th Annual Meeting of the American Society of Hematology 6Kuvan Receives Marketing Approval in the European Union 2Kuvan Receives Marketing Approval in the European Union 3Kuvan Receives Marketing Approval in the European Union 4
(Date:11/24/2009)...arctica has long held secrets of the earth,s histo...here has been very little information on the envir... for millions of years. Now, a team of researchers...funded to the tune of $10 million dollars by the N...bottom of things literally. These scientists will...
(Date:11/24/2009)...vember 24, 2009) New research on bacterial commun... reveals predictable temporal patterns, suggesting...rkers for monitoring climate change in the polar r...ceedings of the National Academy of Sciences Earl... six rivers shifted synchronously over time, corre...
(Date:11/23/2009)...arch presents strong evidence that the "synergisti...raffic-related pollution and indoor endotoxin caus...ther exposure alone. , Environmental health sc...ege of Medicine have shown that children exposed t...d indoor endotoxin during early life are six times...
Breaking Biology News(10 mins):LSU gets to the bottom of things -- in Antarctica 2Researchers establish common seasonal pattern among bacterial communities in Arctic rivers 2Exposure to both traffic, indoor pollutants puts some kids at higher risk for asthma later 2Bioterrorism and disaster preparedness explored in special issue of Medical Decision Making 9378 1Bioterrorism and disaster preparedness explored in special issue of Medical Decision Making 9378 2As Good As a Deli For the Price of Making It At Home 52824 1As Good As a Deli For the Price of Making It At Home 52824 2Molecule plays early role in nonsmoking lung cancer 52821 1Molecule plays early role in nonsmoking lung cancer 52821 2
...that interfere with the action of one particular e...roblems led scientists at Johns Hopkins to create ...w them to see multiple, real-time chemical reacti...ublished July 21 in the journal ACS Chemical Biolo...est chemicals on enzymes isolated from their norma...
...enetic material intact, scientists at Johns Hopkin... vital to managing a yeast cell,s energy. They dis...l of one of them led the cell to turn off 70 perce...ely unprepared for such a dramatic event," says Je...ology and genetics at Hopkins and author of the st...
...ads of Earthlings, arrays of single-cell creatures...le devices are riding on the International Space S...nd the University of New Mexico, NASA and US Air F...ons were directed by yeast and other single cells ... even in the vacuum and radiation of outer space -...
Other Biology News:Hopkins researchers develop new tool to watch real-time chemical activity in cells 2Hopkins researchers develop new tool to watch real-time chemical activity in cells 3Johns hopkins researchers find link between cell's energy use and genome health 2Johns hopkins researchers find link between cell's energy use and genome health 3Sandia work launched on space shuttle shows live cells influence growth of nanostructures 2Sandia work launched on space shuttle shows live cells influence growth of nanostructures 3Sandia work launched on space shuttle shows live cells influence growth of nanostructures 4Sandia work launched on space shuttle shows live cells influence growth of nanostructures 5
Mouse Anti-Human MYO7A Monoclonal Antibody, Unconjugated, Clone 1D3 from Abnova Corporation
..., Functionally-Validated, Ion Channel Cell Lines ...l role in nerve and muscle function and consequent... Drugs that modulate ion channels have been invest...ain, cardiac arrhythmia, hypertension, local anaes...
Mouse Anti-Human TTC3 Monoclonal Antibody, Unconjugated, Clone 2D10 from Abnova Corporation
Mouse Anti-Human SYT4 Polyclonal Antibody, Unconjugated from Abnova Corporation
Biology Products: